Publiseringer

Konferansebidrag og faglig presentasjon

• Simulering som forberedelse til teammottak av akutt syke kreftpasienter

  2025:

  Karoline Skedsmo,

  Torunn Mittet,

  Ingvil Schau Ystgaard,

  Julian Hamfjord

• Incidence patterns of colorectal cancer in Norway 1993-2022 by age, site, and morphology

  2024:

  Mari Fjørtoft Ystgaard,

  Tor Åge Myklebust,

  Jørgen Smeby,

  Inger Kristin Larsen,

  Tormod Kyrre Guren,

  Elin Wenche Hegland Kure

• Initial safety data from the phase 3 POLAR BEAR trial in elderly or frail patients with diffuse large cell lymphoma, comparing R-pola-mini-CHP and R-mini-CHOP

  2023:

  Mats Jerkeman,

  Sirpa Leppä,

  Julian Hamfjord,

  Peter Brown,

  Sara Ekberg,

  Andrés José María Ferreri

• Elevated protein expression levels of KRAS in Pancreatic Ductal Adenocarcinoma (PDAC) are associated with better prognosis.

  2023:

  Stina Margrethe Stålberg,

  Laxmi Silwat-Pandit,

  Julian Hamfjord,

  Daniel JH Nebdal,

  Janne Lehtiö,

  Bjørn Steen Skålhegg

• Identified palliative care needs at start of radiotherapy for painful bone metastases

  2018:

  Ellen Bjerkeset,

  Nina Kathrine Aass,

  Asta Bye,

  Julian Hamfjord,

  Marianne Jensen Hjermstad,

  Jon Håvard Loge

Tidsskriftspublikasjon

• Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal Cancer

  2024:

  Julian Hamfjord,

  Tormod Kyrre Guren,

  Bengt Glimerius,

  Halfdan Sorbye,

  Per Pfeiffer,

  Olav Dajani
• Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis

  2022:

  Louise B. Callesen,

  Tana Takacova,

  Julian Hamfjord,

  Florian Würschmidt,

  Karl J. Oldhafer,

  Roland Brüning
• Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma

  2022:

  Anand Khadse,

  Vilde Drageset Haakensen,

  Laxmi Silwal-Pandit,

  Julian Hamfjord,

  Patrick Micke,

  Johan Botling
• Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis

  2022:

  Louise B. Callesen,

  Julian Hamfjord,

  Anders K. Boysen,

  Niels Pallisgaard,

  Tormod Kyrre Guren,

  Elin Wenche Hegland Kure
• Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer

  2021:

  Julian Hamfjord,

  Tormod Kyrre Guren,

  Bengt Glimelius,

  Halfdan Sorbye,

  Per Pfeiffer,

  Olav Dajani
• Survival Trends of Right- and Left-Sided Colon Cancer across Four Decades: A Norwegian Population-Based Study

  2021:

  Julian Hamfjord,

  Tor Åge Myklebust,

  Inger Kristin Larsen,

  Elin Wenche Hegland Kure,

  Bengt Glimelius,

  Tormod Kyrre Guren
• Using process indicators to monitor documentation of patient-centred variables in an integrated oncology and palliative care pathway—results from a cluster randomized trial

  2021:

  Marianne Jensen Hjermstad,

  Julian Hamfjord,

  Nina Kathrine Aass,

  Olav Dajani,

  Tonje Lundeby,

  Torunn Elin Wester
• Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy

  2019:

  Julian Hamfjord,

  Tormod Kyrre Guren,

  Olav Dajani,

  Julia Sidenius Johansen,

  Bengt Glimelius,

  Halfdan Sorbye
• Total circulating cell-free DNA (cfDNA) as a prognostic biomarker in metastatic colorectal cancer prior to first-line oxaliplatin-based chemotherapy

  2018:

  Julian Hamfjord,

  Tormod Kyrre Guren,

  Olav Dajani,

  Bengt Glimelius,

  Halfdan Sorbye,

  Per Pfeiffer
• AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin

  2016:

  Janne Beathe Kjersem,

  Maria Thomsen,

  Tormod Kyrre Guren,

  Julian Hamfjord,

  G Carlsson,

  B. Gustavsson
• Differential expression of miRNAs in pancreatobiliary type of periampullary adenocarcinoma and its associated stroma

  2016:

  Vandana Sandhu,

  Inger Marie Bowitz Lothe,

  Knut Jørgen Labori,

  Martina Skrede,

  Julian Hamfjord,

  Astrid Marie Larsen
• Serum N-glycome characterization in patients with resectable periampullary adenocarcinoma

  2015:

  Julian Hamfjord,

  Radka Saldova,

  Henning Stockmann,

  Vandana Sandhu,

  Inger Marie Bowitz Lothe,

  Trond Buanes
• High ABCC2 and low ABCG2 gene expression are early events in the colorectal adenoma-carcinoma sequence

  2015:

  Vibeke Andersen,

  Lotte K. Vogel,

  Tine Iskov Kopp,

  Mona Sæbø,

  Annika W. Nonboe,

  Julian Hamfjord
• Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas

  2015:

  Vandana Sandhu,

  Inger Marie Bowitz Lothe,

  Knut Jørgen Labori,

  Ole Christian Lingjærde,

  Trond Buanes,

  Astrid Marie Dalsgaard
• Intestinal PTGS2 mRNA Levels, PTGS2 Gene Polymorphisms, and Colorectal Carcinogenesis

  2014:

  Lotte K. Vogel,

  Mona Sæbø,

  Helle Høyer,

  Tine Iskov Kopp,

  Ulla Vogel,

  Sine Godiksen
• Low ABCB1 Gene Expression Is an Early Event in Colorectal Carcinogenesis

  2013:

  Vibeke Andersen,

  Ulla Vogel,

  Sine Godiksen,

  Franz B. Frenzel,

  Mona Sæbø,

  Julian Hamfjord
• Molecular responses to toxicological stressors: Profiling microRNAs in wild Atlantic salmon (Salmo salar) exposed to acidic aluminum-rich water

  2013:

  Elin H. Kure,

  Mona Sæbø,

  Astrid Marie Dalsgaard,

  Julian Hamfjord,

  Sigurd Hytterød,

  Jan Heggenes
• Differential Expression of miRNAs in Colorectal Cancer: Comparison of Paired Tumor Tissue and Adjacent Normal Mucosa Using High-Throughput Sequencing

  2012:

  Julian Hamfjord,

  Astrid Marie Stangeland,

  Timothy Hughes,

  Martina Skrede,

  Magne Kjell Tveit,

  Tone Ikdahl Andersen
• Let-7 miRNA-binding site polymorphism in the KRAS 3 ' UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab

  2012:

  Janne Beathe Kjersem,

  Tone Ikdahl Andersen,

  Tormod Kyrre Guren,

  Eva Skovlund,

  Halfdan Sorbye,

  Julian Hamfjord
• Wobble-enhanced ARMS Method for Detection of KRAS and BRAF Mutations

  2011:

  Julian Hamfjord,

  Astrid Marie Stangeland,

  Martina Skrede,

  Magne Kjell Tveit,

  Tone Ikdahl Andersen,

  Elin H. Kure
• The multidrug resistance 1 (MDR1) gene polymorphism G-rs3789243-A is not associated with disease susceptibility in Norwegian patients with colorectal adenoma and colorectal cancer; a case control study

  2009:

  Vibeke Andersen,

  Lene Agerstjerne,

  Dorte Jensen,

  Mette Østergaard,

  Mona Sæbø,

  Julian Hamfjord

Bok eller del av bok/rapport

• Ufattelige lidelser : hvorfor atomvåpen må forbys

  2016:

  John Gunnar Mæland,

  Julian Hamfjord,

  Bjørn Hilt,

  Kirsten Kjelsberg Osen

Diverse

• Hva er egentlig kreft?, Krafttak hos Kloppen

  2017:

  Julian Hamfjord
• KRAS mutational test for metastatic colorectal cancer patients: not just a technical problem

  2012:

  Elin H. Kure,

  Julian Hamfjord,

  Astrid Marie Larsen,

  Magne Kjell Tveit,

  Tone Ikdahl